Clinical Trials Browser

Phase 2 × Platinum-resistant Ovarian Cancer × Clear all

NCT06710288 2025-10-20

A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer

Phase 2 Recruiting

Platinum-resistant Ovarian Cancer

NCT04374630 2025-09-10

PROFECTA-II

Phase 2 Completed

Platinum-resistant Ovarian Cancer

NCT05736952 2023-05-11

Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer

Phase 2 Withdrawn

Platinum-resistant Ovarian Cancer

NCT04376073 2020-11-25

ANNIE

Phase 2 Unknown

Platinum-resistant Ovarian Cancer